Overview
- 3 public-safe observations are available for this inspection.
- 3 structured CFR citations are represented.
- 4 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
5 Feb 2026
21 CFR 211.100(b)
SOPs not followed / documented
Cited by Vijaya L Simhadri, Jennifer L Reed, Brentley S Pittman, Katarzyna I Jankowska
5 Feb 2026
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Vijaya L Simhadri, Jennifer L Reed, Brentley S Pittman, Katarzyna I Jankowska
5 Feb 2026
21 CFR 600.80(c)(1)(i)
Reporting Requirements - 15-day alert
Cited by Vijaya L Simhadri, Jennifer L Reed, Brentley S Pittman, Katarzyna I Jankowska
Inspected site
GTGrifols Therapeutics LLCClayton, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.100(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 600.80(c)(1)(i) | Cited across public-safe Form 483 observations | 1x |
Source document
PDF
PDF available
Form 483 source document
The source document is available to authorized Atlas users.
Full 483 report
Get the verbatim text of all 3 observations
The source PDF, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere